Current Treatment Options in Allergy

, Volume 4, Issue 2, pp 268–282 | Cite as

Management of Respiratory Symptoms Induced by Non-Steroidal Anti-Inflammatory Drugs

  • Inmaculada Doña
  • María Salas
  • Esther Barrionuevo
  • Paloma Campo
Drug Allergy (MJ Torres Jaén, Section Editor)
First Online:
  • 35 Downloads
Part of the following topical collections:
  1. Topical Collection on Drug Allergy

Opinion Statement

Non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (NERD) is defined by the combination of chronic rhinosinusitis, nasal polyps, bronchial asthma, and hypersensitivity reactions involving upper and/or lower airways after the exposure to acetylsalicylic acid (ASA) and other NSAIDs. However, airway inflammation occurs even in the absence of exposure to these drugs, leading to disease progression with aggressive polyp formation and non-optimal controlled asthma and rhinosinusitis. In this review, we discuss current and potential management strategies of NERD. This management should be multidisciplinary and comprise medical and surgical treatment of the underlying diseases. In order to prevent reactions due to NSAIDs, avoidance of COX-1 inhibitors with provision of safe therapeutic alternatives should be indicated. However, avoidance of NSAIDs does not ensure disappearance of the airway inflammation and this progresses and persists for life. ASA desensitization followed by daily ASA therapy remains the gold standard of NERD treatment. It is indicated in patients with uncontrolled bronchial and nasal symptoms as well as in patients who require NSAID treatment for specific diseases, such as rheumatic or cardiovascular conditions. ASA desensitization improves upper and lower respiratory symptoms, reduces the need for new nasal surgeries and increases quality of life. Different ASA desensitization protocols have been reported, although the addition of intranasal ketorolac and lysine aspirin prior to an oral ASA schedule has made ASA desensitization safer and more efficient. New therapeutic strategies are being investigated and may provide an alternative treatment for those patients in which ASA desensitization are contraindicated or continuous ASA therapy is discontinued because of adverse effects. Among them, biologic agents are an important treatment option, useful for controlling symptoms of the upper and lower airways. More investigation studies into the mechanisms involved in NERD are needed in order to identify additional therapeutic targets.

Keywords

Acetylsalicylic acid ASA Asthma Desensitization Non-steroidal anti-inflammatory drugs NSAIDs Omalizumab Rhinosinusitis 
This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

Conflict of Interest

Inmaculada Doña, María Salas, Esther Barrionuevo and Paloma Campo declare that they have no conflict of interest. The present study has been supported by the Andalusian Regional Ministry Health (grant: PI-0463-2013). Inmaculada Doña holds a “Juan Rodes” research contract (JR15/00036) supported from the Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness, RETIC ARADYAL (RD16/0006/0001) (grants cofunded from the European Social Fund (ESF)).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Quiralte J et al. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol. 1996;98(3):678–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2002;89(5):474–8.PubMedCrossRefGoogle Scholar
  3. 3.
    •• Stevenson DD, White AA. Clinical characteristics of aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):643–55. This paper reviews the characteristic features of patients with NERD. Features that suggest a diagnosis of NERD include severe sinus, polyp recurrence postoperatively, marked anosmia, alcohol intolerance and hypersensitivity reactions to ASA or other NSAIDs.PubMedCrossRefGoogle Scholar
  4. 4.
    Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16(3):432–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Walters KM, Woessner KM. An overview of nonsteroidal antiinflammatory drug reactions. Immunol Allergy Clin North Am. 2016;36(4):625–41.PubMedCrossRefGoogle Scholar
  6. 6.
    • Rajan JP et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–81 e1. This metanalysis determines the prevalence of NERD among asthmatic adults, being higher among patients with severe asthma, nasal polyps and chronic rhinosinusitis.PubMedCrossRefGoogle Scholar
  7. 7.
    Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Mascia K et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116(5):970–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Choi JH, Kim MA, Park HS. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2014;14(1):1–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Kay LJ, Yeo WW, Peachell PT. Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation. Br J Pharmacol. 2006;147(7):707–13.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Liu T et al. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. Proc Natl Acad Sci U S A. 2013;110(42):16987–92.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum. 2002;46(8):2201–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Choi JH, Kim JH, Park HS. Upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2015;15(1):21–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Mullol J, Picado C. Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33(2):163–76.PubMedCrossRefGoogle Scholar
  15. 15.
    Nizankowska-Mogilnicka E et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy. 2007;62(10):1111–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Miller B et al. Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis. Clin Exp Allergy. 2013;43(8):874–80.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Becker AB, Abrams EM. Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol, 2017.Google Scholar
  18. 18.
    National Asthma, E. andP. Prevention Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma-summary report. J Allergy Clin Immunol. 2007;120(5 Suppl):S94–138.Google Scholar
  19. 19.
    • Macy E et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172–4. In this paper, Macy et al. describe protocols and requirements for ASA desensitization and challenge and discussed the prechallenge of patients and maintenance of ASA desensitization.PubMedCrossRefGoogle Scholar
  20. 20.
    Simon RA, Dazy KM, Waldram JD. Update on aspirin desensitization for chronic rhinosinusitis with polyps in aspirin-exacerbated respiratory disease (AERD). Curr Allergy Asthma Rep. 2015;15(3):508.PubMedCrossRefGoogle Scholar
  21. 21.
    •• Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136(6):1431–40. quiz 1441. This paper reviews current and future treatments for rhinosinusitis, including classical paharmacotherapy options such as glucocorticosteroids and antibiotics, as well as new approaches including humanized monoclonal antibodies: omalizumab, reslizumab, mepolizumab and dupilumab.PubMedCrossRefGoogle Scholar
  22. 22.
    Waldram JD, Simon RA. Performing aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):693–703.PubMedCrossRefGoogle Scholar
  23. 23.
    Ledford DK, Lockey RF. Aspirin or nonsteroidal anti-inflammatory drug-exacerbated chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2016;4(4):590–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Woessner KM, White AA. Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014;133(1):286–7. e1-9.PubMedCrossRefGoogle Scholar
  25. 25.
    Kim YJ et al. Cross-reactivity to acetaminophen and celecoxib according to the type of nonsteroidal anti-inflammatory drug hypersensitivity. Allergy, Asthma Immunol Res. 2014;6(2):156–62.CrossRefGoogle Scholar
  26. 26.
    Neubauer PD, Schwam ZG, Manes RP. Comparison of intranasal fluticasone spray, budesonide atomizer, and budesonide respules in patients with chronic rhinosinusitis with polyposis after endoscopic sinus surgery. Int Forum Allergy Rhinol. 2016;6(3):233–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Mastalerz L et al. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy. 1997;52(9):895–900.PubMedCrossRefGoogle Scholar
  28. 28.
    Martinez-Devesa P, Patiar S. Oral steroids for nasal polyps. Cochrane Database Syst Rev. 2011;7:CD005232.Google Scholar
  29. 29.
    Van Zele T et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069–76. e4.PubMedCrossRefGoogle Scholar
  30. 30.
    Lal D, Hwang PH. Oral corticosteroid therapy in chronic rhinosinusitis without polyposis: a systematic review. Int Forum Allergy Rhinol. 2011;1(2):136–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Aasbjerg K et al. Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes. Respir Med. 2013;107(12):1852–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Bonfils P, Halimi P, Malinvaud D. Adrenal suppression and osteoporosis after treatment of nasal polyposis. Acta Otolaryngol. 2006;126(11):1195–200.PubMedCrossRefGoogle Scholar
  33. 33.
    Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 1991;144(4):957–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Nasser SM et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax. 1994;49(8):749–56.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Dahlen SE et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Lee DK et al. Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J. 2004;24(2):226–30.PubMedCrossRefGoogle Scholar
  37. 37.
    Israel E et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis. 1993;148(6 Pt 1):1447–51.PubMedCrossRefGoogle Scholar
  38. 38.
    Dahlen B et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1187–94.PubMedCrossRefGoogle Scholar
  39. 39.
    Ta V, White AA. Survey-defined patient experiences with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(5):711–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Berges-Gimeno MP, Simon RA, Stevenson DD. The effect of leukotriene-modifier drugs on aspirin-induced asthma and rhinitis reactions. Clin Exp Allergy. 2002;32(10):1491–6.PubMedCrossRefGoogle Scholar
  41. 41.
    White A et al. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol. 2006;97(5):688–93.PubMedCrossRefGoogle Scholar
  42. 42.
    Ragab S et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy. 2001;31(9):1385–91.PubMedCrossRefGoogle Scholar
  43. 43.
    Peters AT et al. Diagnosis and management of rhinosinusitis: a practice parameter update. Ann Allergy Asthma Immunol. 2014;113(4):347–85.PubMedCrossRefGoogle Scholar
  44. 44.
    Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S-50S. quiz 51S.Google Scholar
  45. 45.
    Wallwork B et al. A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. Laryngoscope. 2006;116(2):189–93.PubMedCrossRefGoogle Scholar
  46. 46.
    Videler WJ et al. Long-term low-dose antibiotics in recalcitrant chronic rhinosinusitis: a retrospective analysis. Rhinology. 2012;50(1):45–55.PubMedGoogle Scholar
  47. 47.
    Campo P et al. Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. Allergy. 2013;68(8):1001–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Buchheit KM, Laidlaw TM. Update on the management of aspirin-exacerbated respiratory disease. Allergy, Asthma Immunol Res. 2016;8(4):298–304.CrossRefGoogle Scholar
  49. 49.
    Sakalar EG et al. Aspirin-exacerbated respiratory disease and current treatment modalities. Eur Arch Otorhinolaryngol, 2016.Google Scholar
  50. 50.
    Khalil HS, Nunez DA. Functional endoscopic sinus surgery for chronic rhinosinusitis. Cochrane Database Syst Rev. 2006;3:CD004458.Google Scholar
  51. 51.
    Dalziel K et al. Endoscopic sinus surgery for the excision of nasal polyps: a systematic review of safety and effectiveness. Am J Rhinol. 2006;20(5):506–19.PubMedCrossRefGoogle Scholar
  52. 52.
    Awad OG et al. Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? Laryngoscope. 2008;118(7):1282–6.PubMedCrossRefGoogle Scholar
  53. 53.
    Joint Task Force on Practice P. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–73.CrossRefGoogle Scholar
  54. 54.
    Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180–6.PubMedCrossRefGoogle Scholar
  55. 55.
    Stevenson DD et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol. 1996;98(4):751–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Kowalski ML et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013;68(10):1219–32.PubMedCrossRefGoogle Scholar
  57. 57.
    White AA, Stevenson DD. Aspirin desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2013;33(2):211–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Sweet JM et al. Long-term effects of aspirin desensitization--treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol. 1990;85(1 Pt 1):59–65.PubMedCrossRefGoogle Scholar
  59. 59.
    Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2007;119(1):157–64.PubMedCrossRefGoogle Scholar
  60. 60.
    Cho KS et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575–81.PubMedCrossRefGoogle Scholar
  61. 61.
    Makowska JS et al. Clinical benefits of aspirin desensitization in patients with nonsteroidal anti-inflammatory drug exacerbated respiratory disease are not related to urinary eicosanoid release and are accompanied with decreased urine creatinine. Allergy Asthma Proc. 2016;37(3):216–24.PubMedCrossRefGoogle Scholar
  62. 62.
    Rozsasi A et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63(9):1228–34.PubMedCrossRefGoogle Scholar
  63. 63.
    Stevenson DD et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol. 1984;73(4):500–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Swierczynska-Krepa M et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol. 2014;134(4):883–90.PubMedCrossRefGoogle Scholar
  65. 65.
    Fruth K et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy. 2013;68(5):659–65.PubMedCrossRefGoogle Scholar
  66. 66.
    Comert S et al. Aspirin 300 mg/day is effective for treating aspirin-exacerbated respiratory disease. Allergy. 2013;68(11):1443–51.PubMedCrossRefGoogle Scholar
  67. 67.
    Havel M et al. Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad. Eur Arch Otorhinolaryngol. 2013;270(2):571–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Esmaeilzadeh H et al. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial. Clin Immunol. 2015;160(2):349–57.PubMedCrossRefGoogle Scholar
  69. 69.
    Berges-Gimeno MP, Simon RA, Stevenson DD. Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2003;90(3):338–41.PubMedCrossRefGoogle Scholar
  70. 70.
    Kowalski ML, Wardzynska A, Makowska JS. Clinical trials of aspirin treatment after desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):705–17.PubMedCrossRefGoogle Scholar
  71. 71.
    Patriarca G et al. Intranasal treatment with lysine acetylsalicylate in patients with nasal polyposis. Ann Allergy. 1991;67(6):588–92.PubMedGoogle Scholar
  72. 72.
    Ogata N, Darby Y, Scadding G. Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol. 2007;121(12):1156–60.PubMedCrossRefGoogle Scholar
  73. 73.
    Howe R et al. Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease. World Allergy Organ J. 2014;7(1):18.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Steinke JW et al. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol. 2009;124(4):724–30. e4.PubMedCrossRefGoogle Scholar
  75. 75.
    Katial RK et al. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol. 2010;126(4):738–44.PubMedCrossRefGoogle Scholar
  76. 76.
    Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol. 2006;118(4):801–4.PubMedCrossRefGoogle Scholar
  77. 77.
    Hope AP et al. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2009;123(2):406–10.PubMedCrossRefGoogle Scholar
  78. 78.
    Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep. 2009;9(2):155–63.PubMedCrossRefGoogle Scholar
  79. 79.
    Cook KA, Stevenson DD. Current complications and treatment of aspirin-exacerbated respiratory disease. Expert Rev Respir Med. 2016;10(12):1305–16.PubMedCrossRefGoogle Scholar
  80. 80.
    White AA, Stevenson DD, Simon RA. The blocking effect of essential controller medications during aspirin challenges in patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2005;95(4):330–5.PubMedCrossRefGoogle Scholar
  81. 81.
    Stevenson DD. Aspirin desensitization in patients with AERD. Clin Rev Allergy Immunol. 2003;24(2):159–68.PubMedCrossRefGoogle Scholar
  82. 82.
    • Lee RU et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol. 2010;105(2):130–5. In this paper the authors compared standard oral ASA desensitization and intranasal ketorolac followed by modified oral ASA desensitization, showing that the use of intranasal ketorolac followed by oral ASA induced fewer lower respiratory reactions, making this protocol effective, safe, and less time-consuming than the standard oral ASA desensitization protocol.PubMedCrossRefGoogle Scholar
  83. 83.
    • Chen JR, Buchmiller BL, Khan DA. An hourly dose-escalation desensitization protocol for aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(6):926–31 e1. In this paper a 1-hour dose-escalation protocol for desensitization patients with NERD is proposed.PubMedCrossRefGoogle Scholar
  84. 84.
    Williams AN et al. The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges. J Allergy Clin Immunol. 2007;120(2):273–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Stevenson DD, White AA. Aspirin desensitization in aspirin-exacerbated respiratory disease: consideration of a new oral challenge protocol. J Allergy Clin Immunol Pract. 2015;3(6):932–3.PubMedCrossRefGoogle Scholar
  86. 86.
    Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. Allergy, Asthma Immunol Res. 2011;3(1):3–10.CrossRefGoogle Scholar
  87. 87.
    Simon RA, Dazy KM, Waldram JD. Aspirin-exacerbated respiratory disease: characteristics and management strategies. Expert Rev Clin Immunol. 2015;11(7):805–17.PubMedCrossRefGoogle Scholar
  88. 88.
    White AA, Stevenson DD. Side effects from daily aspirin treatment in patients with AERD: identification and management. Allergy Asthma Proc. 2011;32(5):333–4.PubMedCrossRefGoogle Scholar
  89. 89.
    Schjerning Olsen AM et al. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. BMJ. 2015;351:h5096.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Segal R et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med. 2003;115(6):462–6.PubMedCrossRefGoogle Scholar
  91. 91.
    • Gevaert P et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6 e1. This study demonstrates the clinical efficacy of omalizumab in the treatment of nasal polyps with comorbid asthma.PubMedCrossRefGoogle Scholar
  92. 92.
    Humbert M et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2(5):525–36 e1.PubMedCrossRefGoogle Scholar
  93. 93.
    Bobolea I et al. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol. 2010;20(5):448–9.PubMedGoogle Scholar
  94. 94.
    Guillen D et al. Aspirin desensitization achieved after omalizumab treatment in a patient with aspirin-exacerbated urticaria and respiratory disease. J Investig Allergol Clin Immunol. 2015;25(2):133–5.PubMedGoogle Scholar
  95. 95.
    Bergmann KC, Zuberbier T, Church MK. Omalizumab in the treatment of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract. 2015;3(3):459–60.PubMedCrossRefGoogle Scholar
  96. 96.
    Menzella F et al. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases. J Asthma Allergy. 2015;8:105–14.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Gevaert P et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989–95. e1-8.PubMedCrossRefGoogle Scholar
  98. 98.
    Gevaert P et al. Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy. 2003;58(5):371–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Simon HU et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol. 1997;158(8):3902–8.PubMedGoogle Scholar
  100. 100.
    Thaci D et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387(10013):40–52.PubMedCrossRefGoogle Scholar
  101. 101.
    Wenzel S et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.PubMedCrossRefGoogle Scholar
  102. 102.
    Pitchford SC et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol. 2003;112(1):109–18.PubMedCrossRefGoogle Scholar
  103. 103.
    Laidlaw TM et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood. 2012;119(16):3790–8.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Klinkhardt U et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther. 2003;73(3):232–41.PubMedCrossRefGoogle Scholar
  105. 105.
    Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2015;135(6):1407–14. quiz 1415.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Lupinetti MD et al. Thromboxane biosynthesis in allergen-induced bronchospasm. evidence for platelet activation. Am Rev Respir Dis. 1989;140(4):932–5.PubMedCrossRefGoogle Scholar
  107. 107.
    Schumacher WA, Steinbacher TE. Thromboxane receptor activation during bronchospasm induced by platelet-activating factor. J Lipid Mediat. 1991;4(1):97–110.PubMedGoogle Scholar
  108. 108.
    Bochenek G et al. A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003;111(4):743–9.PubMedCrossRefGoogle Scholar
  109. 109.
    Hirai H et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med. 2001;193(2):255–61.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Nagata K, Hirai H. The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids. 2003;69(2–3):169–77.PubMedCrossRefGoogle Scholar
  111. 111.
    Uller L et al. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. Respir Res. 2007;8:16.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Inmaculada Doña
    • 1
  • María Salas
    • 1
  • Esther Barrionuevo
    • 1
  • Paloma Campo
    • 1
  1. 1.Allergy UnitMalaga Regional University HospitalMalagaSpain

Personalised recommendations